aTYR PHARMA (ATYR) Enterprise Value (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Enterprise Value came in at -$66.7 million in Q1 2026, up 12.84% YoY from -$59.1 million in Q1 2025, and up 15.43% on a QoQ basis from -$78.9 million in Q4 2025.
aTYR PHARMA (ATYR) Enterprise Value (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Enterprise Value data on file, last reported at -$66.7 million in Q1 2026.
- Quarterly Enterprise Value rose 12.84% year-over-year to -$66.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.7 million (up 12.84% YoY) and the FY2025 annual result came in at -$78.9 million, down 9.08% from the prior year.
- Enterprise Value improved to -$66.7 million in Q1 2026, from -$78.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$66.2 million in Q3 2024 to a low of -$114.6 million in Q1 2023.
- A 5-year average of -$85.3 million and a median of -$80.5 million in 2025 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 38.64% in 2022, down 100.6% in 2022.
- Tracing ATYR's Enterprise Value over 5 years: stood at -$66.3 million in 2022, then tumbled by 48.29% to -$98.4 million in 2023, then increased by 26.48% to -$72.3 million in 2024, then decreased by 9.08% to -$78.9 million in 2025, then grew by 15.43% to -$66.7 million in 2026.
- The last three Enterprise Value figures came in at -$66.7 million (Q1 2026), -$78.9 million (Q4 2025), and -$90.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | -57.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.61 Mn |
| Mar 31, 2026 | -66.71 Mn |
| Dec 31, 2025 | -78.88 Mn |
| Sep 30, 2025 | -90.39 Mn |
| Jun 30, 2025 | -80.54 Mn |
| Mar 31, 2025 | -76.54 Mn |
| Dec 31, 2024 | -72.31 Mn |
| Sep 30, 2024 | -66.17 Mn |
| Jun 30, 2024 | -78.67 Mn |
| Mar 31, 2024 | -84.68 Mn |
| Dec 31, 2023 | -98.35 Mn |
| Sep 30, 2023 | -102.32 Mn |
| Jun 30, 2023 | -108.77 Mn |
| Mar 31, 2023 | -114.57 Mn |
| Dec 31, 2022 | -66.33 Mn |
| Sep 30, 2022 | -77.55 Mn |
| Jun 30, 2022 | -88.73 Mn |
| Mar 31, 2022 | -98.84 Mn |
| Dec 31, 2021 | -108.09 Mn |
| Sep 30, 2021 | -116.53 Mn |